Answers are grounded in this paper and cite their sources.
Phase III prospective study demonstrates 52-week vibegron treatment is safe, well-tolerated, and effective in overactive bladder, indicating its viability for long-term clinical management.
Long-term (52-week) treatment with vibegron is safe, well-tolerated and effective in patients with overactive bladder.
No takes yet. Share an insight, caveat, or question.
Yoshida et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: